Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: The White House | Clear Filter
Summary:President Trump is shown signing an Executive Order to reestablish the Presidential Fitness Test and the President’s Council on Sports, Fitness, and Nutrition.
Sentiment:Policy-focused
Key Claims:
- President Trump signs an Executive Order.
- The Executive Order reestablishes the Presidential Fitness Test.
- The Executive Order concerns the President's Council on Sports, Fitness, and Nutrition.
Potential Market Impact (S&P 500):1/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:0/10
Summary:A White House letter from July 31, 2025, addresses Novartis regarding an Executive Order from May 12, 2025, to implement Most-Favored-Nation (MFN) prescription drug pricing for American patients. The letter states that U.S. drug prices are up to three times higher than in other developed nations due to global freeloading and directs Novartis and other manufacturers to take specific actions within 60 days, including extending MFN pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs across all payers, returning increased revenues from abroad, and allowing direct purchasing at MFN rates. It warns that if manufacturers do not cooperate, the administration will deploy every tool to protect American families from abusive pricing, demanding binding commitments by September 29, 2025.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to establish Most-Favored-Nation (MFN) prescription drug pricing for American patients.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to global freeloading.
- Drug manufacturers, including Novartis, are directed to implement specific actions within 60 days.
- These actions include extending MFN pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs across all payers, repatriating increased revenues from abroad to American patients, and enabling direct purchasing at MFN rates.
- The administration will deploy "every tool" to combat abusive drug pricing if cooperation is not met.
- Binding commitments for these goals are required by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10
Summary:The post is a letter from the White House, dated July 31, 2025, to Gilead Sciences, Inc., demanding that the company and all drug manufacturers adopt 'Most-Favored-Nation' (MFN) drug pricing for American patients, extending it to Medicaid, new drugs, and direct purchasing, and repatriating revenues from abroad to lower U.S. drug prices, or face consequences from the Administration.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to ensure Americans pay the same drug prices as other developed nations.
- Brand name drug prices in the U.S. are up to three times higher than elsewhere for identical medicines.
- Current proposals from the industry involve 'shifting blame' and 'handouts.'
- Drug manufacturers must commit to providing immediate relief from inflated drug prices.
- Gilead Sciences, Inc., and all manufacturers are called upon to extend MFN pricing to existing Medicaid drugs.
- Manufacturers must guarantee MFN pricing for newly-launched drugs for Medicare, Medicaid, and commercial payers.
- Increased revenues from abroad must be repatriated to lower U.S. drug prices.
- Manufacturers should participate in direct-to-consumer/business distribution models for MFN pricing.
- Secretary Kennedy and Administrator Oz are ready to implement these terms.
- The Administration will deploy 'every tool in our arsenal' if drug manufacturers refuse to comply.
- Other nations have been 'freeloading' on U.S. innovation.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:A letter from The White House, dated July 31, 2025, to Pfizer CEO Albert Bourla, outlines an Executive Order signed on May 12, 2025, aimed at ending high drug prices in the United States by mandating Most-Favored-Nation pricing for all drugs for American patients, and warns of consequences if drug manufacturers do not comply within 60 days.
Sentiment:Authoritative Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to implement Most-Favored-Nation (MFN) drug pricing for American patients.
- American drug prices are up to three times higher than in other developed nations due to 'global freeloading'.
- The Administration demands Pfizer and all drug manufacturers extend MFN pricing to Medicaid patients for existing drugs.
- The Administration demands Pfizer and all drug manufacturers guarantee MFN pricing for newly-launched drugs for all payers.
- The Administration demands increased revenues from abroad be repatriated to lower US drug prices.
- The Administration demands participation in direct purchasing models at MFN pricing.
- Non-compliance will result in the deployment of 'every tool in our arsenal' to protect American families.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:5/10
Summary:The White House, on July 31, 2025, sent a letter to Novo Nordisk, outlining an Executive Order signed on May 12, 2025, that mandates drug manufacturers adopt Most-Favored-Nation (MFN) pricing for American patients, including for existing drugs via Medicaid and for new drugs for all payers. The letter claims that American patients currently pay up to three times more for brand-name drugs due to global freeloading and demands that increased revenues from higher prices charged abroad be repatriated to benefit American patients and taxpayers. It instructs manufacturers to implement direct purchasing at MFN pricing and warns that non-compliance by September 29, 2025, will result in the deployment of every available tool.
Sentiment:Directive
Key Claims:
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to 'global freeloading.'
- Drug manufacturers must extend Most-Favored-Nation (MFN) pricing to Medicaid for their full portfolio of existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues obtained abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Manufacturers must provide for direct purchasing at MFN pricing through Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) distribution models for high-volume, high-rebate prescription drugs.
- Refusal to comply will result in the deployment of 'every tool in our arsenal to protect American families from continued abusive drug pricing practices.'
- Binding commitments to achieve these goals are required by September 29, 2025.
- Secretary Kennedy and Administrator Oz are part of the team ready to implement these terms.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:1/10
Potential Global Cross-Asset Impact:6/10
Summary:A letter from the White House dated July 31, 2025, sent to Amgen, demands that drug manufacturers implement actions within 60 days, by September 29, 2025, to lower prescription drug prices for American patients to Most-Favored-Nation rates. The letter asserts that the US currently pays significantly more for brand name drugs than other developed nations due to 'global freeloading' and highlights an Executive Order signed on May 12, 2025, aimed at addressing this disparity.
Sentiment:Directive
Key Claims:
- An Executive Order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than elsewhere, attributed to 'global freeloading' and an 'unacceptable burden' on American families.
- Amgen and all manufacturers are called upon to implement specific actions within 60 days to address inflated drug prices.
- Required actions include extending Most-Favored-Nation (MFN) pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs, returning increased revenues from abroad to American patients and taxpayers, and providing for direct purchasing at MFN pricing.
- The administration is prepared to deploy 'every tool in our arsenal' to protect American families from 'abusive drug pricing practices' if manufacturers do not comply.
- The deadline for achieving these goals is September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10
Summary:The post asserts that Q2 GDP data validates economic policies, specifically tariffs, and refutes earlier skeptical predictions from various media outlets regarding economic performance and potential damage.
Sentiment:Vindicative
Key Claims:
- Q2 GDP data proves that media predictions regarding economic outcomes were incorrect.
- Media outlets had previously expressed skepticism about Trump's tariffs and their economic impact.
- Reports suggested Trump's economic revival efforts were falling short in his first 100 days.
- Media outlets claimed that Trump's actions would result in economic damage.
- The Q2 GDP data demonstrates the success of Trump's economic policies, contrary to media narratives.
Potential Market Impact (S&P 500):3/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:2/10
Summary:President Donald Trump signs an executive order aimed at saving college sports, as depicted in an image showing him addressing a large crowd.
Sentiment:Campaigning
Key Claims:
- President Donald Trump signs an Executive Order to Save College Sports.
Potential Market Impact (S&P 500):1/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:0/10
Summary:President Donald Trump signs executive orders on Artificial Intelligence, as depicted in an official image from The White House.
Sentiment:Policy-focused
Key Claims:
- President Donald Trump signed executive orders concerning Artificial Intelligence.
Potential Market Impact (S&P 500):2/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:2/10
Summary:The post attributes $5.2 trillion in secured investments to "The Trump Effect," visually linking Donald Trump to a period of significant economic achievement under the White House's purview.
Sentiment:Triumphant
Key Claims:
- Donald Trump's influence, termed 'The Trump Effect,' led to substantial economic gains.
- A total of $5.2 trillion in investments was secured under this influence.
Potential Market Impact (S&P 500):4/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:3/10